Helixgate https://validator.w3.org/feed/docs/rss2.html Home STAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem STAT+: Former banker brought on to revitalize Pfizer’s strategy departs his post Synthetic Biology and Tissue Engineering Grow Liver Tissue In‑Body STAT+: In early trial, CAR-T results raise hope of preventing multiple myeloma in high-risk patients Trump, FDA plan to expedite psychedelic development RFK Jr. defends HHS tenure, 12% proposed budget cut Novartis cuts two programs in cancer-related blood clots Lilly to Acquire Kelonia for Up to $7B, Expanding Cancer Cell Therapy Pipeline STAT+: Trump order to advance psychedelic treatments generates excitement — and worries AACR 2026: Cancers of Unknown Primary Identified by DNA Methylation AI Model Viatris recalls extended-release Xanax over dissolution test failure Nektar surges again as alopecia drug shows new promise in extension study Merck partner reveals bispecific data; Biogen pays $100M for antibody rights STAT+: The PBMs fight back, and arbitration doesn’t lose Boehringer Ingelheim to expand its AI footprint in UK, in £150M investment Biotech has become a good news story. Let the sun shine Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal Agenus cancer cocktail records 0% response rate, missing midstage goal Novo’s late-stage sickle cell win piles pressure on competitors STAT+: Finally cracking KRAS as a druggable target Lilly to buy Kelonia for $3.25B upfront, underlining its in vivo CAR-T strategy AACR: Endeavoring to go global, Zai Lab offers reality check on China’s biotech ascent STAT+: Pharmalittle: We’re reading about Trump boosting psychedelic treatment, the future for weight-loss drugs, and more Decoding Resistance to Targeted Therapy via New Cancer Models FDA Policy Tracker 2026: Psychedelics get a boost STAT+: The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades Odyssey tests IPO waters anew after quitting quest last year Lilly publishes data confirming Foundayo’s safety profile 10x Genomics Unveils Atera Spatial Platform at AACR Meeting [Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services Nektar’s long-term mid-stage alopecia data fuels Phase 3 plans What actually drives speed in complex drug development programs Three gene therapy pioneers just won the Breakthrough Prize. This is their story From Product to Patient in Nuclear Medicine: Why Vertical Integration Is Essential for a Competitive Advantage KRAS drugmakers take another, better swing at lung cancer UCB plots epilepsy expansion with $650M Neurona cell therapy acquisition Odyssey Therapeutics will try again to IPO, this time in a warmer market STAT+: AACR 2026: More strong data for Revolution Medicines’ KRAS drug StockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analysts How Trump is pushing psychedelics reform through the health agencies Optimism for Trump’s CDC pick is tempered by questions about RFK Jr.’s role RevMed’s stunning success; FDA to reclassify peptides; and more Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’ UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B Tunneling Neurons in Adult Bird Brains Provide New Insights into Neurogenesis Targeted Gene Delivery Calms Lung Inflammation in Respiratory Infection Mouse Models STAT+: A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment New CDC pick Schwartz is praised by public health pros